The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Month: September 2024

Viome Raises $25M To Launch Diagnostic Division
Finance

Viome Raises $25M To Launch Diagnostic Division

SEP 11, 2024
Lallemand inaugurates new research and development laboratories
Finance

Lallemand inaugurates new research and development laboratories

SEP 5, 2024
IBT’s phase III study shows a significant reduction in the secondary endpoint, all-cause mortality
Clinical & Manufacturing

IBT’s phase III study shows a significant reduction in the secondary endpoint, all-cause mortality

SEP 4, 2024
ZBiotics Raises $12M Series A to bring genetically engineered probiotic products to market
Biotics and Supplements

ZBiotics Raises $12M Series A to bring genetically engineered probiotic products to market

SEP 2, 2024
Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus
Clinical & Manufacturing

Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus

SEP 1, 2024
A virally-encoded tRNA neutralizes the PARIS antiviral defense system
Pharma & Human Health

A virally-encoded tRNA neutralizes the PARIS antiviral defense system

SEP 1, 2024
Revealing the mysteries within microbial genomes
Pharma & Human Health

Revealing the mysteries within microbial genomes

SEP 1, 2024
Morinaga Milk Obtains the Registration of “New Food Ingredient” in China for use of its Probiotic Bifidobacterium infantis M-63 in Infant Foods
Biotics and Supplements

Morinaga Milk Obtains the Registration of “New Food Ingredient” in China for use of its Probiotic Bifidobacterium infantis M-63 in Infant Foods

SEP 1, 2024
Researchers develop probiotic to ameliorate ulcerative colitis
Biotics and Supplements

Researchers develop probiotic to ameliorate ulcerative colitis

SEP 1, 2024